Multivisceral transplant is a viable treatment option for patients with non‐resectable intra‐abdominal fibromatosis
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Transplantation"
DOI: 10.1111/ctr.13186
Abstract: Intra‐abdominal fibromatosis often involves the mesentery root which is non‐resectable by conventional surgery. Multivisceral transplant (MVT), as a potential cure to non‐resectable fibromatosis, has rarely been reported and the prognosis is unknown. read more here.
Keywords: multivisceral transplant; intra abdominal; fibromatosis; abdominal fibromatosis ... See more keywords
Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.4011
Abstract: 4011Background: Most ESCC pts have advanced disease at time of diagnosis. Chemotherapy (CTX) is used to improve quality of life (QoL) and overall survival (OS), but still with limited impact. Prior... read more here.
Keywords: resectable advanced; panitumumab patients; cisplatin panitumumab; pts non ... See more keywords
Multimodal treatment strategies for colorectal liver metastases.
Sign Up to like & getrecommendations! Published in 2021 at "Swiss medical weekly"
DOI: 10.4414/smw.2021.20390
Abstract: Colorectal cancer is the third most common cancer worldwide. Half of CRC patients develop liver metastases during the course of the disease, with a 5-year survival rate close to zero in the absence of therapy.… read more here.
Keywords: treatment; colorectal liver; liver; liver metastases ... See more keywords